Navigation Links
PLEXERA® LLC Launches Contract Research Services Business for Biomolecular Interaction Studies
Date:1/16/2013

Seattle Washington (PRWEB) January 16, 2013

Plexera®, LLC, a worldwide provider of label-free surface plasmon resonance imaging (SPRi) technology solutions for functional proteomics, announced today the official launch of its contract research effort based in offices of Plexera LLC located at the Institute for Systems Biology (ISB). Plexera will perform advanced kinetic interaction analysis on either customer provided samples or Plexera provided targets and libraries.

“Through the use of array-formatted label-free, real-time detection and a diverse choice of surface chemistries, customers can avoid the changes to molecular interactions introduced by chemical and biological labeling techniques” says Dr. Zhang, director of Applications at Plexera.

Applications include high-throughput screening, affinity analysis, and specificity determination. Complete service provides custom NanoCapture® chip chemistry selection and preparation, ligand generation and characterization, multiple array production, full kinetic data and analysis, and a full service report. Plexera will take advantage of extensive laboratory facilities at ISB to offer customers a fully integrated service including immunoassay and MS analysis in addition to SPRi studies. The company has completed several studies to date including , small molecule screening, glycoprotein profiling , antibody epitope mapping, and pair antibody screening, and is also aggressively forming collaborative partnerships with leading academic institutions in the US and Asia. Most recently the company shipped and installed a system at RIKIN in Japan to study small molecule/protein binding interactions. The company also announced it has manufactured and shipped its 18th PlexArray® HT system since launched in 2011 and has been awarded its 11th patent surrounding the SPRi technology.

“We are very pleased with the depth of our patent portfolio and the ever increasing inventory of application developments we have made over the last year.” Says Dr. Jinsong Zhu, CEO, Plexera LLC. “As indicated by customer interest the HT application for interaction studies is certainly an emerging commercial technology today.”

ABOUT PLEXERA, LLC.
Plexera LLC (http://www.plexera.com) is a Washington state company providing advanced SPRi-based solutions for functional proteomics. The company has development and manufacturing facilities at its headquarters in Woodinville, WA and has application laboratories in Seattle at the Institute for Systems Biology. The company is exclusively represented for development and marketing in Guangzhou, China by Guangzhou Gaotong Biotechnology Co., Ltd. and PuRui TongLiang Beijing Biotechnology company Ltd. in Beijing. In Japan, the company is exclusively represented by Cell Produce Co., Ltd.
The PlexArray® HT System is a high-throughput, label-free, SPR-based biomolecular interaction detection system for producing high quality information on kinetics, affinities, and specificities among proteins, peptides, small molecules, and genetic materials. The PlexArray HT serves a wide range of industries including pharmaceutical, biomarker R&D, and assay development. A variety of samples can be measured in 15 minutes and thousands of molecule interactions in only 30 minutes. NanoCapture® Biosensor Chips feature high array density (>1,000 spots interrogated simultaneously), variable array spot size (=100 µm), and multiple surface chemistries for protein, nucleic acid, small molecule, or live cell immobilization.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10320468.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Savory, LLC Launches Website and Blog for Water Filtration Systems
2. AkAsha International Launches Children's Book Series
3. NIH launches collaborative effort to find biomarkers for Parkinsons
4. Dr. S. Mark McKenna CEO of ShapeMed (Atlanta, GA) Launches Innovative Fitness App Nationwide
5. U.S. Launches Extensive Alzheimers Studies
6. Dr. Harvey’s Launches "Oracle": a Revolutionary Freeze-Dried, Highly Nutritious and Protein-Rich Line of Complete Foods for Dogs and Cats
7. Marketing Xocolate International Corporation (MXI Corp) Launches “The Whole Story” World Tour To Highlight Xocai Healthy Chocolate Product, Full-Line Up of Guest Speakers
8. LeftBrainRightBrainTest.com Launches New and Informative Test
9. Educational First Steps Launches Four Steps to Excellence 2.0 Program
10. Dr. Vonda Wright, MD. Launches 13-Week "Guide to Thrive" Blog
11. Tiger Schulmann’s MMA Launches New Improved Website and Blog
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for ... 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device ... of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: